While Caribou Biosciences Inc has underperformed by -1.49%%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CRBU fell by -16.98%, with highs and lows ranging from $3.00 to $0.66, whereas the simple moving average fell by -11.48% in the last 200 days.
On June 03, 2024, Evercore ISI Downgraded Caribou Biosciences Inc (NASDAQ: CRBU) to In-line. A report published by Cantor Fitzgerald on November 08, 2023, Initiated its previous ‘Neutral’ rating for CRBU. Evercore ISI also rated CRBU shares as ‘Outperform’, setting a target price of $13 on the company’s shares in an initiating report dated October 31, 2023. Truist Initiated an Buy rating on July 11, 2023, and assigned a price target of $23. RBC Capital Mkts initiated its ‘Outperform’ rating for CRBU, as published in its report on February 18, 2022. Oppenheimer’s report from December 01, 2021 suggests a price prediction of $36 for CRBU shares, giving the stock a ‘Outperform’ rating. H.C. Wainwright also rated the stock as ‘Buy’.
Analysis of Caribou Biosciences Inc (CRBU)
Further, the quarter-over-quarter decrease in sales is -3.13%, showing a negative trend in the upcoming months.
One of the most important indicators of Caribou Biosciences Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -52.76% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 7.63, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and CRBU is recording 1.13M average volume. On a monthly basis, the volatility of the stock is set at 6.34%, whereas on a weekly basis, it is put at 4.65%, with a gain of 18.92% over the past seven days. Furthermore, long-term investors anticipate a median target price of $9.14, showing growth from the present price of $1.32, which can serve as yet another indication of whether CRBU is worth investing in or should be passed over.
How Do You Analyze Caribou Biosciences Inc Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 12.94%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 50.40% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
CRBU shares are owned by institutional investors to the tune of 50.40% at present.
